'No reason to slow down anything here': CureVac plans to march on with Covid-19 vaccine after pivotal failure
The day after CureVac revealed its mRNA vaccine failed a pivotal trial, crushing the company’s stock, a group of analysts tuned into the company call with variations of the same question: What’s next for CVnCoV?
CureVac’s shares $CVAC were down nearly 49% on Thursday morning, after announcing an interim vaccine efficacy of just 47% against Covid-19 disease of any severity. The company blamed its efficacy issues on emerging variants, arguing that the vaccine’s late entry left researchers in an “increasingly challenging variant-rich environment,” with 13 strains circulating, CEO Franz-Werner Haas said on a call with investors Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.